evaluation of il-2 and il-7 expression in patients with prostate cancer

Background: prostate cancer is a biologically heterogeneous disease which has become the fifth leading cause of cancer-related deaths in men worldwide. interleukins (ils) display required inflammation moderator. il-2 and il-7 play significant roles in regulating cancer-immune system interactions. so, the purpose of this investigation was to evaluate the expression level of il-2 and il-7 in prostate cancer patients and healthy subjects. materials and methods: in this case-control study, expression of il-2 and il-7 was examined in peripheral blood of 40 prostate cancer patients and 40 healthy subjects by reverse transcription quantitative real-time polymerase chain reaction. results: our findings showed that il-7 has highly elevated expression in patients with prostate cancer compared to healthy subjects (p=0.0001). in contrast, no significant difference was observed in the expression of the il-2 between the two study groups (p=0.12). conclusion: based on the results, il-7 may be used as a prospective biomarker or as a molecular target in designing new prostate cancer control strategies. however, the findings of this investigation revealed no association between il-2 expression and prostate cancer. nevertheless, more studies should be included to appraise the exact relevance of this gene to prostate cancer.